Description

Adenosine Cyclic Phosphate (cAMP) is a pivotal secondary messenger in intracellular signal transduction, playing a crucial role in regulating metabolic processes, gene expression, and cellular responses to external stimuli. This high-purity compound, with the molecular formula C₁₀H₁₂N₅O₆P and CAS number 60-92-4, is essential for researchers studying cell signaling pathways, neurotransmission, and hormonal regulation. Our cAMP is rigorously tested for purity (≥98.5% by HPLC) and stability, ensuring reliable performance in biochemical assays, cell culture studies, and pharmacological research. Available as a lyophilized powder, it is soluble in aqueous buffers and compatible with a wide range of experimental conditions. Store at -20°C to maintain optimal stability and activity.

Properties

• CAS Number: 60-92-4
• Complexity: 498
• IUPAC Name: (4aR,6R,7R,7aS)-6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol
• InChI: InChI=1S/C10H12N5O6P/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(16)7-4(20-10)1-19-22(17,18)21-7/h2-4,6-7,10,16H,1H2,(H,17,18)(H2,11,12,13)/t4-,6-,7-,10-/m1/s1
• InChI Key: IVOMOUWHDPKRLL-KQYNXXCUSA-N
• Exact Mass: 329.05252012
• Molecular Formula: C10H12N5O6P
• Molecular Weight: 329.21
• SMILES: C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)OP(=O)(O1)O
• Topological: 155
• Monoisotopic Mass: 329.05252012
• Physical Description: Solid
• Melting Point: 219-220 °C
• Solubility: 4 mg/mL
• Synonyms: Cyclic AMP, cAMP, 60-92-4, Adenosine 3′,5′-cyclic monophosphate, 3′,5′-cyclic AMP, Adenosine 3′,5′-cyclophosphate, Adenosine 3′,5′-phosphate, cyclic 3′,5′-AMP, Adenosine cyclic monophosphate, Cyclic Adenosine Monophosphate, cyclic 3′,5′-Adenylic acid, Adenosine 3′,5′-monophosphate, cyclic Adenosine 3′,5′-phosphate, Adenosine cyclic 3′,5′-monophosphate, Cyclic adenylic acid, 3′,5′-AMP, Adenosine 3′,5′-cyclic phosphate, Adenosine cyclic 3′,5′-phosphate, cyclic Adenosine 3′,5′-monophosphate, CCRIS 4291, Adenosine cyclic phosphate, NSC 94017, adenosine-3′,5′-cyclic-monophosphate, CHEBI:17489, BRN 0052645, EINECS 200-492-9, UNII-E0399OZS9N, E0399OZS9N, 3′,5′-cAMP, DTXSID8040436, cyclic-AMP, adenosine-3′,5′-cyclic monophosphate, adenosine-cyclic-phosphate, adenosine cyclic-monophosphate, 3′ 5′-adenosine monophosphate, adenosine-cyclic-phosphoric-acid, DTXCID6020436, ADENOSINUM CYCLOPHOSPHORICUM, 4-26-00-03618 (Beilstein Handbook Reference), NSC-143670, adenosine 3′,5′-(hydrogen phosphate), Adenosine cyclic 3′,5′-(hydrogen phosphate), adenosine cyclic-3′,5′-monophosphate, 3′,5′-Monophosphate, Adenosine Cyclic, ADENOSINE CYCLIC-3′,5′-(HYDROPHOSPHATE), ADENOSINE-3′:5′-CYCLIC MONOPHOSPHORIC ACID (3:5-CYCLIC AMP), NSC-94017, adenosine-3′,5′-monophosphate, AMP, Cyclic, cyclic-3′,5′-adenosine monophosphate, Cyclic Monophosphate, Adenosine, Monophosphate, Adenosine Cyclic, Adenosine Cyclic 3,5 Monophosphate, Adenosine Cyclic 3′,5′ Monophosphate, Cyclic 3′,5′-Monophosphate, Adenosine, Cyclic-3′,5′-Monophosphate, Adenosine, 3’5′-cyclic ester of AMP, Adenosine Cyclic 3′:5′-Monophosphate, 200-492-9, Adenosine cyclophosphate, Adenosine-3′,5′-cyclophosphate, Adenosine, cyclic 3′,5′-(hydrogen phosphate), [3H]cAMP, [3H]-cAMP, Adenosine 3′,5′-phosphate monohydrate, CHEMBL316966, (4aR,6R,7R,7aS)-6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol, 114697-05-1, MFCD00005845, (4aR,6R,7R,7aS)-6-(6-amino-9H-purin-9-yl)-2,7-dihydroxy-hexahydro-1,3,5,2^{5}-furo[3,2-d][1,3,2^{5}]dioxaphosphinin-2-one, NCGC00093588-03, Adenosine 3,5′-cyclic monophosphoric acid, (4aR,6R,7R,7aS)-6-(6-Amino-9H-purin-9-yl)-2,7-dihydroxytetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine 2-oxide, Adenosine-3′,5′-cyclic phosphate, CAS-60-92-4, 3’5′-cyclic AMP, Cyclic AMP (Standard), CYCLIC AMP; CAMP, CYCLIC AMP [MI], Cyclic 3′,5′-adenylate, bmse000071, Epitope ID:137352, SCHEMBL1244, Lopac0_000084, CYCLIC AMP [WHO-DD], GTPL2352, GTPL5096, cAMP; 3′,5′-Cyclic AMP, BDBM10851, HY-B1511R, MSK6937, cid_23902375, HMS3260A10, HY-B1511, Tox21_113510, Tox21_500084, Adenosine-3′,5′-cyclicmonophosphate, BDBM50384264, s9370, Adenosine 3O,5O-cyclic monophosphate, Adenosine 3′,5′-cyclophosphoric acid, Adenosine 3′:5′-cyclic monophosphate, Adenosine 3,5′-cyclic monophosphorate, AKOS015999561, Tox21_113510_1, 3′, 5′-cyclic adenosine monophosphate, Adenosine 3′-,5′-cyclic monophosphate, CCG-204179, DB02527, LP00084, NA08991, SDCCGSBI-0050072.P002, Adenosine 3a(2),5a(2)-cyclophosphate, Adenosine-3′,5′-cyclophosphate (cAMP), NCGC00093588-01, NCGC00093588-02, NCGC00093588-04, NCGC00093588-06, NCGC00260769-01, AS-13112, ADENOSINUM CYCLOPHOSPHORICUM [HPUS], Adenosine, 3′,5′-cyclic-monophosphoric acid, CS-0013299, EU-0100084, NS00122387, ADENOSINE-3 ,5 -CYCLIC-MONOPHOSPHATE, A 9501, A51099, C00575, Q210041, SR-01000075695, CYCLIC-3′,5′-(HYDROGEN PHOSPHATE)ADENOSINE, SR-01000075695-1, Cyclic AMP;cAMP;D-Adenosine 3′,5′-cyclic monophosphate, 4H-Furo[3,2-d]-1,3,2-dioxaphosphorin, adenosine deriv., B5C9F048-77DD-4170-A624-23C09E7B080D, Adenosine 3′,5′-cyclic monophosphate, >=98.5% (HPLC), powder, Adenosine 3 inverted exclamation marka,5 inverted exclamation marka-cyclic monophosphate, CAMP;Adenosine 3 inverted exclamation marka,5 inverted exclamation marka-cyclic monophosphat, (1S,6R,8R,9R)-8-(6-aminopurin-9-yl)-3-hydroxy-3-oxo-2,4,7-trioxa-3^{5}-phosphabicyclo[4.3.0]nonan-9-ol, (2R,4aR,6R,7R,7aS)-6-(6-amino-9H-purin-9-yl)tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-2,7-diol 2-oxide, (4aR,6R,7R,7aS)-6-(6-amino-9H-purin-9-yl)-2,7-dihydroxy-hexahydro-1,3,5,2^{5}-furo[3,2-d][1,3,2]dioxaphosphinin-2-one, (4aR,6R,7R,7aS)-6-(6-amino-9H-purin-9-yl)tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-2,7-diol 2-oxide, (4aR,6R,7R,7aS)-6-(6-Aminopurin-9-yl)-2-oxo-tetrahydro-2-lambda*5*-furo[3,2-d][1,3,2]dioxaphosphinine-2,7-diol, 4H-furo[3,2-d]-1,3,2-dioxaphosphorin-7-ol, 6-(6-amino-9H-purin-9-yl)tetrahydro-2-hydroxy-, 2-oxide, (4aR,6R,7R,7aS)-, 6-(6-Amino-9H-purin-9-yl)tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-2,7-diol 2-oxide #

Adenosine Cyclic Phosphate (cAMP) is widely used in biomedical research to investigate G-protein-coupled receptor (GPCR) signaling, protein kinase A (PKA) activation, and ion channel modulation. It serves as a key tool in studying metabolic disorders, cardiovascular diseases, and neuronal plasticity. Researchers also utilize cAMP in drug discovery to screen for compounds that modulate adenylate cyclase activity or phosphodiesterase inhibition. Its applications extend to cell-based assays, ELISA, and Western blotting for quantifying intracellular signaling events.

Safety and Hazards

GHS Hazard Statements

• H314 (16.7%): Causes severe skin burns and eye damage [Danger Skin corrosion/irritation]
• H315 (50%): Causes skin irritation [Warning Skin corrosion/irritation]
• H318 (16.7%): Causes serious eye damage [Danger Serious eye damage/eye irritation]
• H319 (50%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
• H335 (50%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]

Precautionary Statements

• P260, P261, P264, P264+P265, P271, P280, P301+P330+P331, P302+P352, P302+P361+P354, P304+P340, P305+P351+P338, P305+P354+P338, P316, P317, P319, P321, P332+P317, P337+P317, P362+P364, P363, P403+P233, P405, and P501

Hazard Classes and Categories

• Skin Corr. 1B (16.7%)
• Skin Irrit. 2 (50%)
• Eye Dam. 1 (16.7%)
• Eye Irrit. 2 (50%)

If you are interested or have any questions, please contact us at support@atomfair.com

Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.